Skyclarys Patent Expiration

Skyclarys is a drug owned by Reata Pharmaceuticals Inc. It is protected by 7 US drug patents filed from 2023 to 2024 out of which none have expired yet. Skyclarys's patents will be open to challenges from 28 February, 2027. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 24, 2033. Details of Skyclarys's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US8993640 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Apr, 2033

(8 years from now)

Active
US9701709 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Apr, 2033

(8 years from now)

Active
US8124799 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
Dec, 2029

(5 years from now)

Active
US9670147 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
Apr, 2029

(4 years from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11091430 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
Apr, 2029

(4 years from now)

Active
US8440854 Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17
Apr, 2029

(4 years from now)

Active
US11919838 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
Apr, 2029

(4 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Skyclarys's patents.

Given below is the list of recent legal activities going on the following patents of Skyclarys.

Activity Date Patent Number
Patent litigations
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US8124799
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US8440854
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US9670147
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US9701709
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US11091430
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US8993640
Recordation of Patent eGrant 05 Mar, 2024 US11919838
Recordation of Patent Grant Mailed 05 Mar, 2024 US11919838
Patent eGrant Notification 05 Mar, 2024 US11919838
Email Notification 05 Mar, 2024 US11919838


FDA has granted several exclusivities to Skyclarys. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Skyclarys, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Skyclarys.

Exclusivity Information

Skyclarys holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2030. Details of Skyclarys's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 28, 2028
Orphan Drug Exclusivity(ODE-427) Feb 28, 2030

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Skyclarys is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Skyclarys's family patents as well as insights into ongoing legal events on those patents.

Skyclarys's Family Patents

Skyclarys has patent protection in a total of 34 countries. It's US patent count contributes only to 20.4% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Skyclarys.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Skyclarys's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 24, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Skyclarys Generics:

There are no approved generic versions for Skyclarys as of now.





About Skyclarys

Skyclarys is a drug owned by Reata Pharmaceuticals Inc. It is used for treating Friedrich's ataxia by activating the NRF2 pathway to reduce oxidative stress in adults and adolescents aged 16 years and older. Skyclarys uses Omaveloxolone as an active ingredient. Skyclarys was launched by Reata Pharms in 2023.

Approval Date:

Skyclarys was approved by FDA for market use on 28 February, 2023.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Skyclarys is 28 February, 2023, its NCE-1 date is estimated to be 28 February, 2027.

Active Ingredient:

Skyclarys uses Omaveloxolone as the active ingredient. Check out other Drugs and Companies using Omaveloxolone ingredient

Treatment:

Skyclarys is used for treating Friedrich's ataxia by activating the NRF2 pathway to reduce oxidative stress in adults and adolescents aged 16 years and older.

Dosage:

Skyclarys is available in capsule form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
50MG CAPSULE Prescription ORAL


Skyclarys News

Biogen exceeds projections and raises future forecasts due to success of Alzheimer's drug Leqembi and other new treatments.

01 Aug, 2024

See More